Видео ютуба по тегу Abemaciclib

4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC
4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC
Age-stratified findings from the monarchE trial of abemaciclib in breast cancer
Age-stratified findings from the monarchE trial of abemaciclib in breast cancer
#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 study
#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 study
Expert Discusses Promise of Abemaciclib for Breast Cancer Treatment
Expert Discusses Promise of Abemaciclib for Breast Cancer Treatment
5-year monarchE results: abemaciclib + ET in high-risk EBC
5-year monarchE results: abemaciclib + ET in high-risk EBC
Understanding Abemaciclib: A New CDK4/6 Inhibitor
Understanding Abemaciclib: A New CDK4/6 Inhibitor
Verzenio for Breast Cancer (The good & BAD news) What you need to know!
Verzenio for Breast Cancer (The good & BAD news) What you need to know!
Dr. Ellis on Abemaciclib in HR-Positive Breast Cancer
Dr. Ellis on Abemaciclib in HR-Positive Breast Cancer
monarchE: adjuvant abemaciclib in HR+ breast cancer
monarchE: adjuvant abemaciclib in HR+ breast cancer
EP. 10 | My experience with Verzenio (Abemaciclib) // high risk stage 3 breast cancer
EP. 10 | My experience with Verzenio (Abemaciclib) // high risk stage 3 breast cancer
#abemaciclib | Uses, Dosage, Side Effects & Mechanism | Verzenio
#abemaciclib | Uses, Dosage, Side Effects & Mechanism | Verzenio
Abemaciclib for HR-Positive Metastatic Breast Cancer
Abemaciclib for HR-Positive Metastatic Breast Cancer
NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer
NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer
monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC
monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC
Continuous Abemaciclib Treatment Leads to Breast Cancer Inhibition | Oncotarget
Continuous Abemaciclib Treatment Leads to Breast Cancer Inhibition | Oncotarget
Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast Cancer
Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast Cancer
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared...
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared...
MONARCH 3: Abemaciclib With Endocrine Therapy for mBC
MONARCH 3: Abemaciclib With Endocrine Therapy for mBC
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-nega...
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-nega...
Advantages to Treating HR+ Patients With Breast Cancer With Abemaciclib
Advantages to Treating HR+ Patients With Breast Cancer With Abemaciclib